左西孟旦與多巴酚丁胺治療急性心力衰竭的成本-效果分析
發(fā)布時(shí)間:2019-07-05 09:54
【摘要】:目的:評(píng)估左西孟旦與多巴酚丁胺治療急性心力衰竭的成本-效果,為我省急性心力衰竭患者治療方案的合理選用提供參考。方法:根據(jù)全球SURVIVE臨床試驗(yàn)數(shù)據(jù),結(jié)合目前我省醫(yī)療及消費(fèi)水平,采用成本-效果分析法分別對(duì)左西孟旦與多巴酚丁胺治療急性心力衰竭的成本-效果及結(jié)果敏感度進(jìn)行分析。結(jié)果:對(duì)于急性心力衰竭患者,短期(5 d)給予左西孟旦治療的人均總成本為10 490.00元,多巴酚丁胺為6 637.18元。成本-效果分析及敏感度試驗(yàn)結(jié)果均表明,我省人均國(guó)內(nèi)生產(chǎn)總值(GDP)左西孟旦相較于多巴酚丁胺的增量成本-效果比我省3倍GDP。結(jié)論:在我省目前的經(jīng)濟(jì)水平下,對(duì)于急性心力衰竭患者,采用左西孟旦的治療方案較傳統(tǒng)藥物具有成本-效果優(yōu)勢(shì)。
[Abstract]:Objective: to evaluate the cost-effectiveness of levosimendan and dobutamine in the treatment of acute heart failure, and to provide reference for the rational selection of treatment schemes for patients with acute heart failure in our province. Methods: according to the global SURVIVE clinical trial data and the current medical and consumption levels in our province, the cost-effectiveness and outcome sensitivity of levosimendan and dobutamine in the treatment of acute heart failure were analyzed by cost-effectiveness analysis. Results: for patients with acute heart failure, the total cost per capita was 10 490.00 yuan and dobutamine 6 637.18 yuan in a short term (5 days). The results of cost-effectiveness analysis and sensitivity test show that the incremental cost-effectiveness of (GDP) per capita in our province is three times higher than that of dobutamine compared with dobutamine. The results of cost-effectiveness analysis and sensitivity test show that the incremental cost-effectiveness of Zoximendan is three times higher than that of dobutamine. Conclusion: at the current economic level in our province, the treatment of acute heart failure with Zuoximendan has the advantage of cost-effectiveness compared with the traditional drug.
【作者單位】: 武漢大學(xué)人民醫(yī)院藥學(xué)部;
【分類號(hào)】:R541.6
[Abstract]:Objective: to evaluate the cost-effectiveness of levosimendan and dobutamine in the treatment of acute heart failure, and to provide reference for the rational selection of treatment schemes for patients with acute heart failure in our province. Methods: according to the global SURVIVE clinical trial data and the current medical and consumption levels in our province, the cost-effectiveness and outcome sensitivity of levosimendan and dobutamine in the treatment of acute heart failure were analyzed by cost-effectiveness analysis. Results: for patients with acute heart failure, the total cost per capita was 10 490.00 yuan and dobutamine 6 637.18 yuan in a short term (5 days). The results of cost-effectiveness analysis and sensitivity test show that the incremental cost-effectiveness of (GDP) per capita in our province is three times higher than that of dobutamine compared with dobutamine. The results of cost-effectiveness analysis and sensitivity test show that the incremental cost-effectiveness of Zoximendan is three times higher than that of dobutamine. Conclusion: at the current economic level in our province, the treatment of acute heart failure with Zuoximendan has the advantage of cost-effectiveness compared with the traditional drug.
【作者單位】: 武漢大學(xué)人民醫(yī)院藥學(xué)部;
【分類號(hào)】:R541.6
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 楊萍;老年急性心力衰竭96例臨床分析[J];川北醫(yī)學(xué)院學(xué)報(bào);2004年03期
2 Gheorghiade M. ;Abraham W.T. ;Albert N.M. ;G.C.Fonarow;馬超;;急性心力衰竭住院患者的入院時(shí)收縮壓、臨床特征和預(yù)后[J];世界核心醫(yī)學(xué)期刊文摘(心臟病學(xué)分冊(cè));2007年04期
3 宋金梅;;急性心力衰竭100例救治體會(huì)[J];鄭州大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2007年05期
4 李培杰;楊小華;鄭寧;杜強(qiáng);;2006美歐急性心力衰竭患者院前及早期住院推薦建議簡(jiǎn)讀[J];中國(guó)急救醫(yī)學(xué);2008年06期
5 趙雁薇;王t,
本文編號(hào):2510443
本文鏈接:http://sikaile.net/yixuelunwen/jjyx/2510443.html
最近更新
教材專著